Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) Equity Ratio (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Equity Ratio for 9 consecutive years, with 0.48 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Equity Ratio fell 22.29% year-over-year to 0.48, compared with a TTM value of 0.48 through Jun 2025, down 22.29%, and an annual FY2024 reading of 0.55, up 83.84% over the prior year.
  • Equity Ratio was 0.48 for Q2 2025 at Autolus Therapeutics, down from 0.55 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.77 in Q4 2021 and bottomed at 0.3 in Q4 2023.
  • Average Equity Ratio over 5 years is 0.57, with a median of 0.58 recorded in 2023.
  • The sharpest move saw Equity Ratio crashed 51.25% in 2023, then skyrocketed 83.84% in 2024.
  • Year by year, Equity Ratio stood at 0.77 in 2021, then fell by 21.15% to 0.61 in 2022, then plummeted by 51.25% to 0.3 in 2023, then surged by 83.84% to 0.55 in 2024, then fell by 11.98% to 0.48 in 2025.
  • Business Quant data shows Equity Ratio for AUTL at 0.48 in Q2 2025, 0.55 in Q4 2024, and 0.58 in Q3 2024.